Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | GUSB | P08236 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CISD2 | Q8N5K1 | 9/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8290467 | 0.77 | ALDH1A1 (0.60) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL3239048 | 0.76 | ALDH1A1 (0.78) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL3050182 | 0.75 | ADORA2A (0.55) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL28224659 | 0.75 | ALDH1A1 (0.50) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL1659875 | 0.73 | ALDH1A1 (0.46) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL5461507 | 0.73 | COMT (0.48) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL21612064 | 0.72 | KDM4E (0.47) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL623740 | 0.71 | ADORA2A (0.71) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL2809243 | 0.71 | MAPT (0.56) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL10298580 | 0.70 | ALDH1A1 (0.53) | MAPTALDH1A1KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208015-A1 | 5-Morpholinylmethylthiophenyl Pharmaceutical Compounds As P38 MAP Kinase Modulators | ASTEX THERAPEUTICS, LTD. (UK) | 2007-09-06 | — | — | US | disclosed |
| US-20070208015-A1 | 5-Morpholinylmethylthiophenyl Pharmaceutical Compounds As P38 MAP Kinase Modulators | ASTEX THERAPEUTICS, LTD. (UK) | 2007-09-06 | — | — | US | disclosed |
| US-20070208015-A1 | 5-Morpholinylmethylthiophenyl Pharmaceutical Compounds As P38 MAP Kinase Modulators | ASTEX THERAPEUTICS, LTD. (UK) | 2007-09-06 | — | — | US | disclosed |
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | ASTEX THERAPEUTICS LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | ASTEX THERAPEUTICS LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | ASTEX THERAPEUTICS LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| EP-1756082-A1 | 5-MORPHOLINYLMETHYLTHIOPHENYL PHARMACEUTIAL COMPOUNDS AS P38 MAP KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006040569-A1 | THIOPHENE AMIDE COMPOUNDS FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
| EP-1615907-A1 | 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | Astex Therapeutics Limited (GB) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005100338-A1 | 5-MORPHOLINYLMETHYLTHIOPHENYL PHARMACEUTIAL COMPOUNDS AS P38 MAP KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-10-27 | — | — | WO | disclosed |
| WO-2004089929-A1 | 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | CNKSR1, NOX5, NOX1 | MAPT 4044/4885ALDH1A1 3896/4885KMT2A 3434/4885 |
| US-20070208015-A1 | 5-Morpholinylmethylthiophenyl Pharmaceutical Compounds As P38 MAP Kinase Modulators | MAPK1, MAPK3, MAPK10 | MAPT 990/4885ALDH1A1 3862/4885KMT2A 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.